BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 32297104)

  • 21. No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
    King AC; Kabel CC; Pappacena JJ; Stump SE; Daley RJ
    Ann Pharmacother; 2019 Sep; 53(9):922-932. PubMed ID: 30841702
    [No Abstract]   [Full Text] [Related]  

  • 22. BRAF V600E mutation in hairy cell leukemia: from bench to bedside.
    Falini B; Martelli MP; Tiacci E
    Blood; 2016 Oct; 128(15):1918-1927. PubMed ID: 27554081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hairy cell leukemia: a 'hair-raising' update.
    Topp ZZ; Saven A
    Expert Rev Hematol; 2014 Oct; 7(5):659-69. PubMed ID: 25148599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF inhibitor therapy in HCL.
    Dietrich S; Zenz T
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):246-52. PubMed ID: 26614903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
    Kreitman RJ; Pastan I
    Oncologist; 2020 Jan; 25(1):e170-e177. PubMed ID: 31628266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biology and Treatment of Hairy Cell Leukemia.
    Paillassa J; Troussard X
    Curr Treat Options Oncol; 2020 Apr; 21(6):44. PubMed ID: 32350628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hairy cell leukemia: update and current therapeutic approach.
    Salam L; Abdel-Wahab O
    Curr Opin Hematol; 2015 Jul; 22(4):355-61. PubMed ID: 26049757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hairy cell leukemia: What are the best treatment options for relapsed or refractory patients?].
    Troussard X; Maitre E; Paillassa J
    Bull Cancer; 2021; 108(7-8):771-778. PubMed ID: 34023063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
    Kreitman RJ; Pastan I
    Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32756468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia.
    Tiacci E; Schiavoni G; Martelli MP; Boveri E; Pacini R; Tabarrini A; Zibellini S; Santi A; Pettirossi V; Fortini E; Ascani S; Arcaini L; Inghirami G; Paulli M; Falini B
    Haematologica; 2013 Apr; 98(4):635-9. PubMed ID: 23349307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. V-raf murine sarcoma viral oncogene homolog B (BRAF) mutations in hairy cell leukaemia.
    Arora N; Nair S; Pai R; Nair S; Ahmed R; Abraham A; Viswabandya A; George B; Balasubramanian P; Srivastava A; Mathews V
    Indian J Pathol Microbiol; 2015; 58(1):62-5. PubMed ID: 25673595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
    Chihara D; Kantarjian H; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Poku R; Jain P; Thompson P; Brandt M; Luthra R; Burger J; Keating M; Ravandi F
    Br J Haematol; 2016 Sep; 174(5):760-6. PubMed ID: 27301277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hairy Cell Leukemia: Where Are We in 2023?
    Mendez-Hernandez A; Moturi K; Hanson V; Andritsos LA
    Curr Oncol Rep; 2023 Aug; 25(8):833-840. PubMed ID: 37097545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
    Troussard X; Maître E; Paillassa J
    Am J Hematol; 2024 Apr; 99(4):679-696. PubMed ID: 38440808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.
    Cornet E; Delmer A; Feugier P; Garnache-Ottou F; Ghez D; Leblond V; Levy V; Maloisel F; Re D; Zini JM; Troussard X;
    Ann Hematol; 2014 Dec; 93(12):1977-83. PubMed ID: 24994538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders.
    Maitre E; Paillassa J; Troussard X
    Front Oncol; 2022; 12():1068981. PubMed ID: 36620555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitor of BRAF
    Smirnova SY; Al-Radi LS; Moiseeva TN; Gemdzhian EG; Yakutik IA; Julhakyan HL; Novikov VA; Galstyan GM; Sudarikov AB
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):427-430. PubMed ID: 33811006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular variant of hairy cell leukemia with poor prognosis.
    Arons E; Kreitman RJ
    Leuk Lymphoma; 2011 Jun; 52 Suppl 2(Suppl 2):99-102. PubMed ID: 21599610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hairy cell leukemia: Past, present and future.
    Getta BM; Park JH; Tallman MS
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):269-72. PubMed ID: 26614906
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.